Novartis AG beats Q2 2025 expectations, but patent expiries and policy risks loom. Click for my updated look at NVS earnings ...

Holdings has accelerated revenue growth and expanded gross margins. Read what supports a compelling long-term investment ...

Pfizer faces a $1 billion sales hit in 2025 from IRA reforms, flat EPS and revenue forecasts, and long-term risks tied to patent expirations.

M Company (MMM) reports better-than-expected Q2 2025 results, raises full-year guidance, driven by growth in all business ...

Pfizer PFE is one of the biggest players in the oncology space — a position it strengthened with the 2023 acquisition of Seagen. The deal added four antibody-drug conjugates (ADC) — Adcetris, Padcev, ...

As earnings season gains momentum, next week’s slate features heavyweights across tech, energy, industrials, and consumer sectors, offering a broad pulse on corporate health and macro conditions.

American Express stock has been stable but unspectacular this year, staying in lockstep with the broader market. With ...

Morgan Stanley (NYSE:MS) has seen a notable shift in its stock ownership as Massachusetts Financial Services Co. MA reduced ...